Therapeutic needs ill the field of analgesia are mainly focused on the reli
ef of chronic pain sustained by either inflammatory or neuropathic mechanis
ms. The high diversity of physiopathological mechanisms supporting chronic
pains make necessary to use many different animal models, a point that is e
thically disputable. In such a way, it may he valuable to characterize the
pharmacology of compounds using irt vitro assays before testing ill vivo th
ose having been selected, In parallel to pharmacological evaluation, it is
proposed to add physicochemical, pharmacokinetic and metabolic ir, vitro as
says in the purpose to predict the availability of new chemical entities in
the body. Furthermore, recombinant methodologies are now allowing to work
with human targets previously introduced into competent cell lines. The ult
imate goal consists to get the highest confidence in predicting in vivo act
ivity and thus, limit the number of molecules to he tested in animals.